Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The Trump administration has withdrawn Heidi Overton's nomination to lead the FDA after she failed to secure enough support on Capitol Hill. Overton faced pushback from Democrats, skeptical Republicans, antiabortion groups, and factions within the MAHA movement. The FDA will now continue under acting Commissioner Kyle Diamantas while the White House searches for a new nominee.
The Trump White House has pulled the plug on Heidi Overton's nomination to lead the Food and Drug Administration, citing a lack of congressional support. Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated by President Trump in August but quickly became a lightning rod for criticism from multiple directions.
Opposition came from Democrats, skeptical Republican senators — including Sen. Bill Cassidy (R-La.), chair of the Senate HELP Committee — antiabortion advocates concerned about her stance on mifepristone prescribing rules, and even factions within the MAHA movement who felt she was too aligned with health and agriculture industry interests. The HELP Committee had been scheduled to vote on her nomination Wednesday before the White House withdrew it.
Key Takeaways:
Why it matters: The FDA plays a central role in drug approvals, food safety, and public health policy. A prolonged leadership vacuum could slow regulatory decision-making and create uncertainty across the healthcare and pharmaceutical industries at a pivotal moment for the agency.